{
    "doi": "https://doi.org/10.1182/blood.V120.21.5163.5163",
    "article_title": "Hereditary Spherocytosis: How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging ",
    "article_date": "November 16, 2012",
    "session_type": "Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron",
    "abstract_text": "Abstract 5163 Introduction: Hereditary Spherocytosis (HS) is one of the most common inherited hemolytic anemias. Many of them are autosomal dominant, being about 25% of the cases transmitted recessively. Diagnostic of HS: Classic testing for HS includes: Hematologic testing of red blood cell indices (RDW, MCHC, Reticulocyte count), peripheral blood smear (presence of spherocytes), osmotic fragility and Eosin-5-maleimide binding to band 3 and Rh-related proteins forms that may be used as screening tests for hereditary spherocytosis. Objective: Recently have been developed new parameters and information in the new automated hematology analyzer called DxH8008\u2122 from Beckman Coulter as @MSCV (@Mean Sphered Cell Volume), @RSF, @MAF, @ LHD%. All this parameters may be used to create flagging for laboratory use only (LUO) or Research use only (RUO). The purpose of this study is to investigate the possible use or utility of this new information for the screening/flagging of Hereditary Spherocytosis. There are previous studies showing the possible benefit of using MCV minus @MSCV for the detection/flagging of cases with spherocytes. Patient and Methods: We have collected 28 patients with Hereditary Spherocytosis. All of them were confirmed by red cell morphology, osmotic fragility and Eosin-5-maleimide binding to band 3 and Rh-related proteins forms. Table 1  Diagnostic . n . NON BETA (control) 184 HbH (alfa thalasemia intermedia) 129 Alfa Thalassemia Heterozygous 48 Beta Thalassemia Trait 30 Hereditary Spherocytosis (study group)  28  Iron Deficiency Anaemia 22 Thalassemia intermedia (Beta-Thal Interm) 18 microdrepanocitosi (Beta-S) 8 Blackfan-Diamond Anemia 3 Dyserithropoietic Anaemia type I (CDA I) 3 Sickle cell anaemia 3 Piruvate-Kinase deficiency 3 IRIDA iron-refractory iron deficiency anemia 3 Fanconi's Anaemia 2 Dyserithropoietic Anaemia type II (CDA II) 2 Hyporegenerative anemia 2 Megaloblastic Anemia 1 Piruvate-Kinase deficiency Splenectomized 1 Hemoglobinopaty (Taybe) + \u03b1-thalassemia 1 Hemoglobinopaty hyperunstable (Hb Cagliari) 1 Hemoglobinopaty Koln 1 Acute Lymphoblastic Leukemia (ALL) 1 Pyropoikilocytosis 1 Evans's Syndrome 1 Diagnostic . n . NON BETA (control) 184 HbH (alfa thalasemia intermedia) 129 Alfa Thalassemia Heterozygous 48 Beta Thalassemia Trait 30 Hereditary Spherocytosis (study group)  28  Iron Deficiency Anaemia 22 Thalassemia intermedia (Beta-Thal Interm) 18 microdrepanocitosi (Beta-S) 8 Blackfan-Diamond Anemia 3 Dyserithropoietic Anaemia type I (CDA I) 3 Sickle cell anaemia 3 Piruvate-Kinase deficiency 3 IRIDA iron-refractory iron deficiency anemia 3 Fanconi's Anaemia 2 Dyserithropoietic Anaemia type II (CDA II) 2 Hyporegenerative anemia 2 Megaloblastic Anemia 1 Piruvate-Kinase deficiency Splenectomized 1 Hemoglobinopaty (Taybe) + \u03b1-thalassemia 1 Hemoglobinopaty hyperunstable (Hb Cagliari) 1 Hemoglobinopaty Koln 1 Acute Lymphoblastic Leukemia (ALL) 1 Pyropoikilocytosis 1 Evans's Syndrome 1 View Large Results: Using ROC analysis, the best parameters differentiating the Hereditary Spherocytosis from the normals were: RET% (AUC 0. 996), MCV - @MSCV (AUC 0. 996), @MSCV (AUC 0. 969), RDW(AUC 0. 892), MCHC (AUC 0. 860), HGB (AUC 0. 787). Using ROC analysis, the best parameters differentiating the Hereditary Spherocytosis from other anemias (excluding normals)were: MCV - @MSCV (AUC 0. 991), MCHC (AUC 0. 987), RET% (AUC 0. 857). Disclosures: Simon-Lopez: Beckman Coulter: @LHD, @MAF, @RSF, @LHD, @MAF, @RSF Patents & Royalties, Employment. Di Gaetano: Instrumentation Laboratory spa: Work for a distributor of Beckman Coulter Instruments in Italy Other. Galanello: Novartis: Research Funding, Speakers Bureau; Apopharma: Research Funding, Speakers Bureau; Ferrokin: Research Funding.",
    "topics": [
        "hereditary spherocytosis",
        "anemia",
        "cisplatin/methotrexate/vinblastine protocol",
        "mean corpuscular hemoglobin concentration determination",
        "mean corpuscular volume analyses",
        "thalassemia",
        "eosine yellowish-(ys)",
        "iron deficiency anemia",
        "maleimides",
        "osmotic fragility"
    ],
    "author_names": [
        "Susanna Barella, MD",
        "Ramon Simon-Lopez, MD",
        "Nicola Di Gaetano, BS, PhD",
        "Renzo Galanello, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Susanna Barella, MD",
            "author_affiliations": [
                "Dipartimento di Scienze Biomediche e Biotecnologie, Universita' di Cagliari. Ospedale Regionale Microcitemie, Cagliari, Italy, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Ramon Simon-Lopez, MD",
            "author_affiliations": [
                "Beckman Coulter Eurocenter, Nyon, Switzerland, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicola Di Gaetano, BS, PhD",
            "author_affiliations": [
                "Hematology, Instrumentation Laboratory spa, Milan, Italy, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Renzo Galanello, MD",
            "author_affiliations": [
                "Ospedale Regional Microcitemie, Cagliari, Italy"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-22T18:46:00",
    "is_scraped": "1"
}